Drug intelligence / Profile preview

FP002

Development stage: Phase 1
Lead developer: Guangdong Fapon Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FP002 is a humanized anti-CD47 IgG4 monoclonal antibody developed and patented by Fapon Biopharma. It binds strongly to the CD47 protein on the surface of tumor cells, acting as a CD47 antagonist, and weakly to human red blood cells without causing hemagglutination. The drug is designed to block the "don't eat me" signal mediated by CD47, thereby promoting phagocytosis of tumor cells by macrophages. Preclinical studies have shown that FP002 demonstrates stronger anti-tumor efficacy and higher reliability compared to similar products in multiple tumor models. It is being developed for use in oncology, specifically for advanced malignancies and solid tumors[2][3][4][6][8].

Other names: FP-002FP002FP 002

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on FP002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FP002.

Explore the full profile